Uses of Gomradin

Gomradin belongs to the group of cardiovascular drugs, indicated in the treatment of high cholesterol, dyslipidemia, and slows down the progression of atherosclerosis. To ensure safety for your health and maximize the effectiveness of your treatment, you need to take Gomradin exactly as directed by your doctor.

Gomradin medicine contains the main active ingredient Rosuvastatin (as Rosuvastatin calcium 20.8mg) with a strength of 20mg. The drug is prepared in the form of film-coated tablets, presented in a box of 1 blister and 4 blisters, 1 blister includes 7 tablets.

Gomradin is indicated for use in the following cases:
Treatment of patients with primary hypercholesterolemia (type IIa including heterozygous familial hypercholesterolemia) or in mixed dyslipidemia (class IIb) when the patient is unable to respond adequately to diet and exercise. Adjunct to diet and with other lipid-lowering measures (eg, LDL apheresis) in homozygous familial hyperlipidemia. The drug helps to slow the progression of atherosclerosis in patients with hypercholesterolemia by reducing low-density lipoprotein cholesterol (LDL-C) and total cholesterol.

How to use Gomradin:
Gomradin is produced in the form of film-coated tablets, used orally, the time of taking Gomradin does not depend on meals, can be taken before, during and after meals. Before treatment with Gomradin, the patient must absolutely adhere to a cholesterol-lowering diet and maintain this regimen throughout the duration of the drug. Dosage of Gomradin:
In adults:
Based on the cholesterol level of each patient, future cardiovascular risk as well as the possibility of adverse effects to choose the right starting dose for each individual. body. The recommended starting dose for Gomradin is 5 to 10 mg once daily. Depending on the goal of treatment, the patient's response is LDL-C level, the dose can be increased to 20mg x 1 time / day, after 4 weeks. In patients with severe hypercholesterolemia and at high cardiovascular risk (especially those with familial hypercholesterolemia), the dose may be increased up to 40 mg when treatment goals are not achieved. at a dose of 20 mg, and close monitoring is required in these patients. In children:
Do not use Gomradin for children, except for a few cases of children with homozygous familial hypercholesterolemia (children > 8 years old). In the elderly:
Use the same dose as in adults. In patients with renal impairment:
For patients with mild to moderate renal impairment, no dose adjustment is necessary, caution should be exercised when using a dose of 20mg in these subjects. Contraindicated to use Gomradin for patients with severe renal failure. In patients with hepatic impairment:
Can be used in patients with Child-Pugh score less than 7, do not use Gomradin in patients with advanced liver disease. Consider a starting dose of Gomradin of 5 mg.

During the use of Gomradin, besides the therapeutic effects, patients may experience the following side effects:
Increase HbA1c; Increased blood sugar ; Muscle pain, headache, weakness; Dizziness, constipation, abdominal pain, nausea; Rash, pruritus, urticaria, cognitive impairment; Rarely rhabdomyolysis, myalgia, hypersensitivity reactions. During the use of Gomradin, if the patient experiences any adverse effects, they should immediately notify the doctor for advice and effective treatment instructions.

Gomradin AUC values ​​may be 7 times higher than those in healthy volunteers when Gomradin and Cyclosporin are co-administered, however, plasma concentrations of Cyclosporin are not affected. INR values ​​may be increased at the start or dose of Gomradin in patients receiving concomitant treatment with Vitamin K antagonists (similar to other HMG-CoA Reductase inhibitors). Cmax, AUC of Gomradin increased 2 times when Gemfibrozil and Gomradin were used concurrently. Antacids containing aluminum and magnesium hydroxide reduce plasma concentrations of Gomradin by approximately 50% when co-administered with antacids, preferably 2 hours after administration of the antacid. For Erythromycin when co-administered with Gomradin can reduce the AUC and Cmax of Gomradin by 20% and 30%.

Gomradin is not indicated for use in the following subjects:
Patients with a history of hypersensitivity to Rosuvastatin or any of the excipients contained in Gomradin. Contraindicated in patients with severe renal impairment, myopathy, active liver disease (including unexplained and persistent elevations in serum transaminases) and serum transaminase levels more than 3 times the upper limit of normal. often. Do not use for patients who are taking Cyclosporin. Do not use in pregnant women, nursing mothers or women of childbearing age who are not using appropriate contraception. Precautions when using Gomradin:
Caution when using Gomradin because of the potential for skeletal muscle effects: Causes muscle pain and uncomplicated myopathy. In patients with hypothyroidism, impaired renal function, history of myopathy due to previous statin or fibrin use, personal/family history of hereditary myopathy, history of liver disease/alcoholism, Patients older than 70 years with risk factors for rhabdomyolysis, need to monitor CK levels and weigh the risks and benefits of treatment with Gomradin.

Store Gomradin medicine in a cool, dry place, avoid direct sunlight or high temperature because these agents can change the substances in the drug, the appropriate storage temperature below 30 degrees C. Keep out of reach of children to limit the risk of using the wrong medicine.